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Abstract
 
Experimental allergic encephalomyelitis (EAE) is an animal model for multiple sclerosis in-
duced by stimulating myelin basic protein (MBP)-specific T cells. The MBP-specific repertoire
in B10.PL mice is shaped by tolerance mechanisms that eliminate MBP121–150–specific T
cells. In contrast, MBPAc1–11–specific T cells escape tolerance and constitute the encephalito-
genic repertoire. To determine if this differential tolerance is caused by differences in the
 
abundance of MBP epitopes generated by processing, MBP peptides were eluted from I-A
 
u
 
complexes and analyzed by mass spectrometry. Peptides were identified from both the NH
 
2
 
-
terminal and MBP121–150 regions. Unexpectedly, MBPAc1–18 and Ac1–17, which contain
the MBPAc1–11 epitope, were much more abundant than MBP121–150 peptides. The results
demonstrate that competition between two I-A
 
u
 
 binding registers, a low affinity register de-
fined by MBPAc1–11 and a high affinity register defined by MBP5–16, prevents most of the
NH
 
2
 
-terminal naturally processed peptides from binding in the MBPAc1–11 register. The
small fraction of MBPAc1–18 bound in the MBPAc1–11 register is not sufficient to induce
tolerance but provides a ligand for MBPAc1–11–specific T cells during disease. These results
provide a basis for both the lack of tolerance to MBPAc1–11 and the ability of this epitope to
become a target during autoimmunity.
Key words: experimental allergic encephalomyelitis • antigen processing • T cell tolerance • 
MHC class II • MBP epitopes
 
Introduction
 
The TCR repertoire generated by random rearrangement
of V, D, and J gene segments includes TCRs specific for
self-antigens. Most self-reactive T cells are eliminated in the
thymus by negative selection mediated by high avidity inter-
actions with peptide/MHC ligands (1). Peripheral tolerance
mechanisms also eliminate or render nonresponsive T cells
that recognize self-antigens under noninflammatory condi-
tions (2). Nevertheless, some T cells escape both central and
peripheral tolerance and cause autoimmune disease when
activated under inflammatory conditions. This phenome-
non is the basis for the induction of experimental allergic
encephalomyelitis (EAE), an animal model of multiple scle-
rosis (MS). EAE is induced by activating self-reactive T cells
 
via immunization with myelin antigens in complete Freund’s
adjuvant or by adoptive transfer of myelin-specific T cells
(3). In the B10.PL strain, almost all T cells primed by immu-
nization with myelin basic protein (MBP) recognize a single
I-A
 
u
 
–restricted epitope contained within MBPAc1–11 (4).
Initially, this observation was interpreted to mean that
MBPAc1–11 was the only epitope processed and presented
by I-A
 
u
 
 molecules and recognized by T cells. However, our
previous studies showed that the MBP-specific repertoire
in B10.PL mice is significantly influenced by immune
 
tolerance mechanisms. In B10.PL MBP-deficient 
 
shiverer
 
(MBP
 
 
 
/
 
 
 
) mice, immunization with MBP elicits strong T
cell responses directed toward MBP121–150 while the
MBPAc1–11–specific T cell response is a minor compo-
nent of the total MBP response (5). Tolerance mechanisms
in MBP
 
 
 
/
 
 
 
 wild-type mice eliminate MBP121–150-spe-
cific but not MBPAc1–11–specific T cells.
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We proposed that differences in the stability of peptide/
MHC ligands caused the differential tolerance induction of
MBPAc1–11 and MBP121–150–specific T cells. Two syn-
thetic peptides, MBP125–135 and MBP136–146, stimu-
lated T cells from MBP-primed mice and both peptides ex-
hibit high affinity for I-A
 
u
 
 (6). In contrast, MBPAc1–11
binds I-A
 
u
 
 poorly (7). These data suggested that one or
both of the MBP125–135 and 136–146 epitopes are pre-
sented on the cell surface in greater abundance than
MBPAc1–11 and therefore mediate tolerance more effec-
tively. Analyses of TCR transgenic (Tg) mice supported
this notion. MBP121–150-specific Tg T cells undergo cen-
tral tolerance mediated by bone marrow–derived cells.
MBP121–150 epitopes are presented constitutively in the
periphery in sufficient quantity to activate naive MBP121–
150-specific Tg T cells adoptively transferred into wild-
type mice (8). However, insufficient ligand is presented in
vivo to induce central tolerance of MBPAc1–11–specific T
cells (9) or trigger their activation in the periphery after
adoptive transfer (8).
To provide direct support for this model of differential
epitope display, we analyzed peptides eluted from I-A
 
u
 
 pu-
rified from MBP-pulsed APCs. We expected to detect pre-
dominantly MBP121–150 peptides and few or no peptides
containing MBPAc1–11. Surprisingly, the predominant
MBP peptides eluted from I-A
 
u
 
 were MBPAc1–17 and
Ac1–18. A nested set of peptides containing MBP125–135
was also detected, but the abundance was 20-fold less than
MBPAc1–17 and Ac1–18. We demonstrate that the abun-
dance of MBPAc1–17 and Ac1–18 results from the pres-
ence of a high-affinity binding register, MBP5–16, that was
previously described as “absolutely cryptic” (10). The re-
sults show that most, but not all, NH
 
2
 
-terminal peptides are
bound in the MBP5–16 register and are not recognized by
MBPAc1–11–specific T cells. Our data define the naturally
processed MBP peptides and identify the type of APC that
presents tolerogenic MBP121–150 epitopes in vivo. The
results provide an explanation for how MBPAc1–11–spe-
cific T cells escape tolerance but mediate disease under in-
flammatory conditions.
 
Materials and Methods
 
Mice.
 
B10.PL(73 NS)/Sn were obtained from The Jackson
Laboratory. MBP
 
 
 
/
 
 
 
 B10.PL mice, MBP1–11- and MBP121–
150-specific TCR transgenic mice have been described previ-
ously (8, 9, 11).
 
Sample Preparation for Mass Spectrometry.
 
MBP was isolated
using a modified protocol of Martenson et al. (12). Briefly, frozen
mouse brains (Pel-Freez Biologicals) were pulverized and lipids
extracted in chloroform/methanol (2:1). Dried residue was ho-
mogenized in 0.3 M HCl and the supernatant was clarified by
centrifugation, dialyzed against 10 mM acetic acid, and lyophi-
lized. Single cell suspensions were prepared from the spleen and
T cell–depleted using anti-TCR biotin (BD Biosciences) and
streptavidin-labeled magnetic beads (Dynal). T cell–depleted
splenocytes (2 
 
 
 
 10
 
6
 
 cells/ml in RPMI) were incubated for 16 h
at 37
 
 
 
C with or without MBP (95 
 
 
 
g/ml). I-A
 
u
 
 was isolated and
peptides eluted according to Luckey (13) using the anti–I-A
 
u
 
 10–
 
3.6.2 antibody (
 
 
 
1 mg/10
 
8
 
 cells) bound to Protein A beads. Pep-
tides were eluted with 10% acetic acid through a 10 kD cutoff
spinfilter (Millipore).
 
Mass Spectrometry.
 
Approximately 6 
 
 
 
 10
 
6
 
 cell equivalents
(ce) of sample spiked with 2 fmol angiotensin I was gradient-
eluted (C18 microcapillary, acetonitrile:water with 0.1 mM ace-
tic acid, 0–70% in 40 min at 57 nL/min) directly into a home-
built FT ion cyclotron resonance mass spectrometer (FT-ICR
MS) as described previously (14). Full-scan mass spectra (300 
 
 
 
m/z 
 
 
 
 5,000) were collected at one scan per second, with typical
resolution of 5,000–10,000 amu. Subtractive analysis software
aligned the data based on the shapes of their total ion chromato-
grams (TIC) and the similarity of masses found in scans at TIC
peaks. Multiple charged ions were deconvoluted and compared
among MBP pulsed and nonpulsed data sets. For peptide identity
verification, 
 
 
 
6 
 
 
 
 10
 
7
 
 ce of the MBP-pulsed sample were gradi-
ent eluted into a ThermoFinnigan LCQ Deca ion trap mass spec-
trometer (ThermoFinnigan) to collect ions with m/z of 300–
2,000 amu and predetermined precursor ions were subjected to
collision-activated dissociation. MS/MS spectra were manually
interpreted and compared with the synthetic peptide MS/MS
fragmentation patterns. Coelution studies were performed by
adding 60 fmol of synthetic peptide to a 6 
 
 
 
 10
 
7
 
 ce sample. Pep-
tide concentrations were estimated by normalizing the ion inten-
sities to the angiotensin internal standard.
 
Peptide Binding Assays.
 
Peptides were synthesized using stan-
dard Fmoc chemistry on an Applied Biosystems 433A peptide
synthesizer (Foster City) and labeled with 
 
N
 
-hydroxysuccini-
midyl ester of 5(6)-carboxyfluorescein before cleavage. Labeling
was on either the NH
 
2
 
 terminus or, for N-acetylated peptides, on
a COOH-terminal lysine selectively deprotected with 2% hydra-
zine. Peptides were high performance liquid chromatography-
purified and their identity confirmed by mass spectrometry. De-
tergent soluble I-A
 
u
 
 was prepared as described (6). A solution of
I-A
 
u
 
 (50–100 nM in 0.2 mM dodecyl maltoside/PBS) was incu-
bated with excess peptide at pH 5.3 at 37
 
 
 
C. Unbound peptide
was removed by size exclusion (Sephadex G50-SF) at 4
 
 
 
C, pH
7.4. The amount of peptide bound to I-A
 
u
 
 was assessed by high
performance size exclusion chromatography (300 mm 
 
 
 
 7.8 mm,
Biosep-SEC-S 3000; Phenomenex) as the amount of fluores-
cence associated with the protein peak. Loss in fluorescence as a
function of time was fit to an exponential function to obtain dis-
sociation half-times.
 
Detection of MBP-presenting APCs.
 
All antibodies were from
BD Biosciences except those indicated. T cells from MBP
 
 
 
/
 
 
 
MBP121–150-specific TCR Tg mice were purified using biotin-
ylated anti-V
 
 
 
2.3 and AutoMACS (Miltenyi Biotec) cell separa-
tion. B220
 
 
 
 B cells were purified using biotinylated anti-B220
and AutoMACS cell separation. Dendritic cells (CD11c
 
 
 
) and
macrophages (F4/80
 
 
 
/ CD11c
 
 
 
) were isolated from splenocytes
depleted of TCR
 
 
 
 and B220
 
 
 
 cells by AutoMACS cell separa-
tion and sorted based on F4/80-PE (Caltag) and CD11c-FITC
using a FACS Vantage™ (Becton Dickinson) cell sorter. Purity
of all populations was greater than 86%. APC subsets (APC num-
bers/well are indicated in Fig. 3) were cultured with 5 
 
 
 
 10
 
4
 
 pu-
rified MBP121–150–specific T cells in 96-well round bottom
plates in complete RPMI. Cultures were incubated 48 h, pulsed
with [H
 
3
 
]-thymidine, and harvested 18 h later. Stimulation index
is calculated as the mean CPM of T cells incubated with wild-
type APCs divided by the mean CPM of T cells incubated with
MBP
 
 
 
/
 
 
 
 APCs.
 
T Cell Proliferation Assays Using Fixed APCs.
 
Assays were
performed as described above except T cells from MBPAc1–T
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11-specific TCR Tg mice were purified by AutoMACs separa-
tion using anti-V
 
 
 
2.3 or V
 
 
 
8.1/8.2 antibodies and then sorted
to remove contaminating I-A
 
u
 
–expressing cells using either
anti-V
 
 
 
2.3 or V
 
 
 
8.1/8.2 and anti-I-A
 
b
 
 (clone AF6–120.1,
cross-reactive to I-A
 
u
 
). Sorted T cells were plated at 2 
 
 
 
 10
 
5
 
/
well with 50 uM peptide or 95 
 
 
 
g/ml whole MBP and 10
 
6
 
 ir-
radiated live or fixed (0.1% paraformaldehyde for 5 min at
room temperature) splenocytes.
 
Results
 
Processing of MBP Generates Two Distinct Nested Sets
of Peptides.
 
The large differences in affinity for I-A
 
u
 
 ob-
served between peptides within MBP121–150 versus
MBPAc1–11 suggested that differential T cell tolerance in-
duction reflected differences in the abundance of peptide/
MHC ligands derived from these regions. A caveat to these
studies is that the synthetic peptides may not represent the
actual epitopes processed from MBP under noninflamma-
tory, tolerizing conditions in vivo. Residues flanking a core
epitope can influence binding to MHC by interacting with
MHC residues outside the binding groove (15). Addition-
ally, processed peptides may contain multiple epitopes that
compete for MHC binding (16). These concerns motivated
us to identify the peptides bound to I-A
 
u
 
 after processing of
whole MBP.
We used differential analysis to identify the MBP pep-
tides bound to I-A
 
u
 
. B10.PL splenocytes were incubated
overnight with whole MBP and this positive sample was
compared with MBP
 
 
 
/
 
 
 
 B10.PL splenocytes incubated
without MBP. I-A
 
u
 
 molecules were purified and peptides
were eluted from both the MBP positive and negative sam-
ples. Peptide masses were analyzed using Fourier transform
ion cyclotron resonance mass spectrometry (FT-ICR-MS).
Total ion chromatograms for each sample are shown in Fig.
1. Peptides present in the positive (MBP pulsed) and absent
in the negative FT-ICR-MS datasets were identified using
subtractive analysis software.
We identified two nested sets of MBP peptides. The
identity of multiple peptides from each set was confirmed
by collision-activated dissociation analyses (CAD) and coe-
lution (Table I). One peptide set corresponded to the NH
 
2
 
terminus of MBP and the other set was derived from the
MBP121–150 region. The most abundant MBP peptides
were MBPAc1–17 and Ac1–18, which were 
 
 
 
20 times
more abundant than peptides from the MBP121–150 re-
gion. Within the MBP121–150 region, only peptides con-
taining the predicted core epitope MBP125–135 and not
MBP136–146 were identified (detection limit estimated at
one copy/cell).
 
The MBP5–16 Binding Register Accounts for the Abundance
of NH
 
2
 
-terminal Peptides.
 
The paradoxical observation that
MBPAc1–17 and Ac1–18 are the most abundant peptides
generated by processing MBP despite the low affinity of
MBPAc1–11 for I-A
 
u
 
 could be due to the presence of a
second more stable binding register within these peptides.
This idea was initially suggested by the observation that rat
MBPAc5–20 and MBPAc9–20 inhibited EAE induced by
immunization with rat MBPAc1–11 by competition for
I-A
 
u
 
 binding (17). Fairchild et al. (10) investigated this
binding register in mouse MBP and implicated the tyrosine
at MBP12 as the anchor residue binding in the p6 pocket of
I-A
 
u
 
. The core peptide binding in this register, MBP5–16,
would be favored relative to the MBPAc1–11 register,
which places an unfavorable lysine (MBP4) in the p6
pocket. However, these earlier studies concluded that the
naturally-processed peptides derived from whole MBP
could not contain both MBPAc1–11 and MBP5–16 (10,
17). Our data demonstrating that MBP processing primar-
ily generates NH
 
2
 
-terminal peptides containing both regis-
ters required us to reconsider this interpretation.
We investigated whether the NH
 
2
 
-terminal peptides
could bind I-A
 
u
 
 using both binding registers by analyzing
the dissociation kinetics of MBPAc1–18 as well as smaller
peptides representing the individual binding registers from
solubilized I-A
 
u
 
. MBP5–16/I-A
 
u
 
 dissociated so slowly that
a half-life was difficult to measure (t
 
1/2
 
 
 
 
 
 1,000 h). The
half-life of MBPAc1–11/I-A
 
u
 
 was only 30 min. Interest-
ingly, MBPAc1–18/I-A
 
u
 
 dissociated with biphasic kinetics,
suggesting that the peptide binds in a mixture of short-lived
and long-lived complexes (Fig. 2 A). Under these binding
conditions (incubation with MHC molecules for 1 h at
37
 
 
 
C), 
 
 
 
38% and 62% of the MBPAc1–18 peptides
formed short- and long-lived complexes, respectively. In-
creasing the incubation time from 1 to 16 h increased the
amount of MBPAc1–18 peptide bound in the long phase
to 77% (unpublished data). Dissociation of analogue pep-
tides with mutations in the p6 anchor residues for each reg-
Figure 1. Total ion chromatograms
(TIC) from the FT-ICR MS analysis of
peptide from MBP-pulsed and unpulsed
samples. Mass spectra acquisitions were re-
corded at 1 s intervals. The majority of the
peptides eluted over a  28 min period dur-
ing the gradient.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
1394
 
Identification of Naturally Processed Peptides of Myelin Basic Protein
 
ister was also analyzed. The MBPAc1–18Y12A substitu-
tion, which abrogates binding in the MBP5–16 register,
exhibits single phase, rapid dissociation essentially identical
to the dissociation of MBPAc1–11 (Fig. 2, A and B). Con-
versely, the MBPAc1–18K4Y substitution, which replaces
the unfavorable lysine with a tyrosine in the anchor posi-
tion of the MBPAc1–11 register, exhibits single phase,
slow-dissociation kinetics with a half-life very similar to the
 
Table I. MBP Peptides Eluted from I-Au Identified by Mass Spectrometry
MBP peptidea Observed mass Calculated mass Scan no. Abundance Copy/cellb CAD Coelution
3-16 545.307 545.309 153 11.7 2.4
3-17 430.994 430.992c 204 51.9 10.4
2-16 430.994 430.992c 204 51.9 10.5
4-17 531.634 531.634 190 181.6 36.3 Yes Yes
Ac1-16 612.010 612.003 321 90.8 18.1
Ac1-17 641.015 641.013 311 2,410.9 484.0 Yes Yes
Ac1-18 674.696 674.696 328 3,112.8 622.0 Yes Yes
Ac1-19 718.738 718.718 438 33.4 6.7
Ac1-20 756.738 756.718 439 122.1 24.4
Ac1-22 619.823 619.814c 428 28.4 5.7
124-137 499.583 499.580 183 46.2 9.2 Yes
124-138 548.609 548.602 319 32.5 6.3 Yes
123-138 567.616 567.610 317 31.4 6.5 Yes
123-136 499.583 499.580 183 46.2 9.2 Yes
122-136 548.609 548.602 319 32.5 6.3 Yes Yes
121-136 567.616 567.610 317 31.4 6.5 Yes
122-137 567.616 567.610 317 31.4 6.5
120-137 450.227 450.222c 363 16.8 3.4
aPeptide identity assigned by matching observed and calculated masses, CAD column indicates confirmed identities. Numbering is based on the se-
quence of the 18.5 kD MBP isoform.
bBased on copy number/cell of MBPAc1-18 which was determined by comparison to angiotensin control.
cObserved masses are from  4 charge state peptides, all other masses are from  3 charge state peptides.
Figure 2. MBPAc1–18 demonstrates biphasic dissociation. (A) Dissociation of fluorescein-labeled MBP peptides from soluble I-Au. MBP peptides
were incubated with soluble I-Au for 1 h at 37 C. For MBPAc1–18,  38% of the original peptide bound was bound in the faster phase: t1/2fast   3.7 h.
About 62% of the initial peptide is bound in the slow phase: t1/2slow   117 h. (B) Expanded time scale of panel A showing the monophasic fast dissocia-
tion of both MBPAc1–18Y12A and MBPAc1–11.T
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slow-dissociation phase of native MBPAc1–18 (Fig. 2 A).
These data confirm the utilization of two binding registers
within MBPAc1–18 and suggest that most, but not all, of
MBPAc1–18 is bound to I-Au in the MBP5–16 register.
MBPAc1–11–specific T Cells Recognize I-Au/Ac1–18 MBP
Complexes on Fixed APCs. The data described above sug-
gest that priming of MBPAc1–11–specific T cells by im-
munization with whole MBP occurs through recognition
of the small amount of MBPAc1–17 and Ac1–18 bound in
the MBPAc1–11 register. This interpretation predicts that
MBPAc1–11–specific T cells should respond to MBPAc1–
18 without additional processing. To test this predic-
tion, we analyzed proliferation of T cells from two dif-
ferent MBPAc1–11–specific TCR Tg lines (9, 11) using
MBPAc1–18 and fixed or live APCs. While only live
APCs could present whole MBP to the T cells, both T cells
responded well to MBPAc1–18 and MBPAc1–11 on fixed
APCs (SIs of 1476 and 784 for MBPAc1–18; 791 and 604
for MBPAc1–11).
Dendritic Cells Constitutively Present MBP121–150 Epitopes
In Vivo. Our results indicated that peptides bound in the
MBP5–16 and MBP125–135 registers form very stable
complexes with I-Au. This suggested that MBP121–150-
specific TCR Tg T cells might detect MBP125–135/I-Au
complexes on APCs directly ex vivo and allow us to iden-
tify the type of APC presenting these epitopes. Mononu-
clear cells from the spleen and lymph nodes were tested for
their ability to stimulate MBP121–150–specific T cells in
vitro without addition of exogenous MBP. MBP121–150–
specific T cells isolated from MBP /  TCR Tg mice pro-
liferated specifically in response to either irradiated spleno-
cytes, pooled brachial, axial, and inguinal lymph node cells
or superficial cervical lymph node cells isolated from wild-
type MBP /  but not MBP /  mice (Fig. 3). Splenocytes
were fractionated based on expression of B220, CD11c,
and F4/80. Only the CD11c  population triggered signifi-
cant proliferation (SI greater than 3), indicating that den-
dritic cells are the major cell type presenting endogenously-
derived MBP121–150 epitopes. Although the amount of
specific T cell proliferation varied for different tissues, no
correlation was observed with either the number of
CD11c  cells or the level of I-Au expression on CD11c 
cells in different tissues, suggesting that differences in pro-
liferation may reflect variation in the amount of MBP
present in a tissue (unpublished data).
Discussion
We identified the peptides generated from processing
whole MBP in B10.PL mice and the APCs that normally
present these peptides in vivo. The most abundant MBP
peptides eluted from I-Au are MBPAc1–17 and MBPAc1–
18. A second set of nested peptides containing the core
MBP125–135 was found at much lower abundance. The
observation that more NH2-terminal than MBP125–135
peptides are presented by APCs is precisely the opposite of
what our T cell tolerance studies predicted. This paradox is
explained by the demonstration that MBPAc1–18 binds to
I-Au using two binding registers, MBPAc1–11 and MBP5–
16. The biphasic dissociation kinetics of MBPAc1–18, as
well as the dissociation rates of analogue peptides shown
in Fig. 2, suggest that most of the MBPAc1–17 and
MBPAc1–18 peptides are bound in the MBP5–16 register.
Processed NH2-terminal peptides truncated at the NH2 ter-
minus (Table I) must also bind in the MBP5–16 register
because they lack important residues required for binding
in the MBPAc1–11 register (18). MBPAc1–11–specific T
cells do not recognize NH2-terminal peptides bound in the
MBP5–16 register and therefore do not encounter suffi-
cient ligand to undergo tolerance induction.
Our data resolve the question of which peptides are gen-
erated by processing the NH2-terminal region of MBP.
This question has been debated for many years because
MBPAc1–11–specific T cells respond to processed whole
MBP in vivo, yet MBPAc1–11 binds very poorly to I-Au
in vitro. Structural studies confirm that MBPAc1–11 binds
I-Au in an energetically unfavorable register in which one
third of the MHC cleft is empty (18). MBP peptides that
extend beyond MBPAc1–11 exhibit stronger binding via a
second register (7, 10), however, it was hypothesized that
processed peptides could not contain both registers because
the more stable register would prevent binding in the
MBPAc1–11 register. This idea was supported by the lack
of MBPAc1–11–specific T cell hybridoma responses to
peptides longer than MBPAc1–13 on fixed APCs in vitro
(10). In contrast to these data, we demonstrate that T cells
expressing two different Tg MBPAc1–11–specific TCRs
Figure 3. MBP121–150–specific Tg T cells respond to dendritic cells
presenting endogenous MBP directly ex vivo. Stimulation index (SI) was
calculated as described in methods. APCs: whole splenocytes (SPL), pe-
ripheral lymph node cells (PLN), or superficial cervical lymph nodes cells
(CLN), B cells (B220 ), dendritic cells (CD11c ), and macrophages (F4/
80 /CD11c ). Numbers of APCs/well are indicated in parentheses. Data
on the left are responses from an individual mouse representative of 22
mice over seven experiments. Variation in SIs for different tissues was seen
between individual mice. Mean, standard deviation, and median of SIs and
the fraction of mice with SIs   2 (respectively) are as follows: SPL (3.6,
2.9, 3.0, 13/22); PLN (19.1, 26.8, 7.7, 19/22); and CLN (6.7, 9.1, 4.5, 19/
22). The data shown on the right are representative from two experiments.T
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respond well to MBPAc1–18 on fixed APCs. The Tg T
cells may be more sensitive compared with the hybridomas
used in earlier experiments. Interestingly, we show that
MBPAc1–11 register binding is enhanced in the longer
MBPAc1–18 peptide relative to MBPAc1–11. The rapid-
dissociation phase for MBPAc1–18 gives an apparent half-
time of 3.7 h as compared with the 30 min half-life ob-
served for MBPAc1–11/I-Au complexes. This is consistent
with our finding that 10-fold less MBPAc1–18 compared
with MBPAc1–11 is needed to stimulate MBPAc1–11–
specific T cells (unpublished data). Thus, the presence
of the MBP5–16 register enhances presentation of the
MBPAc1–11 register rather than inhibiting it.
It was initially surprising that  20 times more
MBPAc1–17 and Ac1–18 than MBP125–135 peptides
were detected in the eluted peptides because all of these
peptides exhibit similar affinities for I-Au. Several factors
may account for enrichment of NH2-terminal peptides.
The most abundant murine MBP isoform purified from
myelin includes the NH2-terminal region but excludes
MBP125–135 (19), resulting in a fivefold enrichment of
NH2-terminal sequences. The ends of a protein may also
be easier to denature and facilitate processing than se-
quences in the middle of the protein. Lastly, the N-acetyl
group may inhibit exopeptidases and protect peptides from
further degradation, consistent with the observation that
nonacetylated NH2-terminal peptides are detected at com-
parable levels to the MBP125–135 peptides (Table I) while
MBPAc1–17 and Ac1–18 are more abundant.
Competition for binding to I-Au between the MBPAc1–
11 and MBP5–16 binding registers provides a mechanistic
explanation for the lack of tolerance induction in
MBPAc1–11–specific T cells. The bias toward the MBP5–
16 register observed in vitro after a 1 h incubation of
MBPAc1–18 with I-Au could be even stronger in vivo be-
cause increasing the incubation to 16 h increased the per-
centage of peptide bound in the MBP5–16 register. The 1 h
incubation time may underestimate the time that I-Au is
exposed to MBP peptides in vivo, considering that there is
approximately a 12 h delay before peptide derived from
endocytosed protein is processed and presented on the sur-
face of activated dendritic cells (20). H-2M activity may
also influence register utilization and is likely to favor the
more energetically stable MBP5–16 register.
The observation that a tolerogenic MBP epitope is de-
tected ex vivo only on dendritic cells supports the domi-
nant role believed to be played by these APCs in maintain-
ing tolerance to auto-antigens. The fact that minute levels
of MBP125–135 peptides on dendritic cells induces toler-
ance suggests that very little MBPAc1–17 and Ac1–18 is
normally bound in the MBPAc1–11 register because it is
insufficient to induce tolerance in MBPAc1–11–specific T
cells. However, peptide bound in the MBPAc1–11 register
is detected by activated MBPAc1–11–specific T cells in
vivo during disease. Detection of MBPAc1–11-bound
Ac1–18 may be enhanced during inflammation by in-
creased presentation of all MBP epitopes due to increased
MBP degradation, increased expression of costimulatory
molecules on APCs and/or increased sensitivity of acti-
vated T cells to antigenic stimulation. Thus, the dynamic
competition between two binding registers allows most
MBPAc1–11–specific T cells to escape tolerance induction
by dendritic cells presenting self-antigen under noninflam-
matory conditions but allows MBPAc1–11–specific T cells
to see sufficient amounts of their epitope under inflamma-
tory conditions to initiate autoimmunity.
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